AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPublished in a peer-reviewed journal
Monitoring Remyelination in Patients with MS
In a study of 101 patients with MS and 20 healthy controls, white matter lesions showed an increase in χdia over one year. This increase was notably greater in patients treated with ofatumumab. Factors like female sex, shorter disease duration, and disability improvement were linked to greater changes in χdia.
- Tags
- #Remyelination
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Other
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
The findings could inform our understanding of remyelination in MS and how specific treatments may impact this process, which is essential for improving patient outcomes.
What this does not prove
The study does not establish clear causation and the small sample size may limit the applicability of the results.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 101 · Number of patients with MS who completed follow-up
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-27
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Remyelination
- Biological target
- χdia
- Pathway
- Not reported
- Population
- Patients with MS and healthy controls
- Size of effect
- p < 0.001
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceMonitoring Remyelination and Its Association With Disability Improvement in Multiple Sclerosis Using APART-QSM: A Longitudinal Cohort Study. ↗DOI: 10.1002/jmri.70601
Supporting passages (19)
study phaseSTAGE OF TECHNICAL EFFICACY: 2.
study designJournal Article
subjectsOne hundred forty-five patients with MS and 65 healthy controls (HCs).
speciesOne hundred forty-five patients with MS and 65 healthy controls (HCs).
sample sizeOne hundred one patients with MS and 20 HCs completed follow-up after a median (IQR) interval of 1.0 (0.8) and 1.25 (0.2) years, respectively.
sample size basisRESULTS: One hundred one patients with MS and 20 HCs completed follow-up after a median (IQR) interval of 1.0 (0.8) and 1.25 (0.2) years, respectively.
peer reviewedJournal of magnetic resonance imaging : JMRI
research categoriesRemyelination
publication date2026-10-27
comparatorPOPULATION: One hundred forty-five patients with MS and 65 healthy controls (HCs).
primary endpointχdia increased in white matter lesions over 1 year; this increase was associated with female sex, shorter disease duration, ofatumumab treatment, and disability improvement, with greater χdia increase earlier in the disease course.
follow upRESULTS: One hundred one patients with MS and 20 HCs completed follow-up after a median (IQR) interval of 1.0 (0.8) and 1.25 (0.2) years, respectively.
mechanismsAccordingly, IterAtive magnetic suscePtibility sources sepARaTion quantitative susceptibility mapping, which could separate myelin‐sensitive (χdia) and iron‐sensitive (χpara) susceptibility signals, was used to monitor χdia and χpara changes in patients with MS in this longitudinal study.
biological targetsχdia
populationOne hundred forty-five patients with MS and 65 healthy controls (HCs).
effect sizep < 0.001
findingsRESULTS: One hundred one patients with MS and 20 HCs completed follow-up after a median (IQR) interval of 1.0 (0.8) and 1.25 (0.2) years, respectively. At baseline, white matter lesions (WMLs) exhibited lower χdia (0.0131 [IQR 0.0087] ppm) and higher χpara (0.0058 [IQR 0.0049] ppm) than corresponding normal-appearing white matter (NAWM) (0.0191 [0.0088] ppm; 0.0036 [0.0038] ppm; both p < 0.001). Over 1 year, χdia in WMLs increased (0.0122 [IQR 0.0069] vs. 0.0152 [IQR 0.0065] ppm, p < 0.001), particularly in ofatumumab-treated patients (0.0114 [IQR 0.0085] vs. 0.0158 [IQR 0.0081] ppm, p < 0.001). Greater increases in χdia were significantly associated with female sex, ofatumumab treatment, relapsing-remitting phenotype, and EDSS improvement (all Bonferroni correction p < 0.01). Δχdia showed a nonlinear decline with increasing disease duration (effective degrees of freedom (edf) = 1.83, p = 0.002).
limitationsTitle: Monitoring Remyelination and Its Association With Disability Improvement in Multiple Sclerosis Using APART-QSM: A Longitudinal Cohort Study.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.